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Issue, and Another Exciting Biennial ISPOR ConferenceIt is our pleasure to present a new annual issue of Value in Health
Regional Issues from the Latin American (LA) region, and a good
opportunity to provide our readership with fresh news about the
ISPOR 5th LA Conference recently held in Chile. Let us start with
the latter, and then get to the former.
ISPOR LA meetings started 8 years ago, with nearly 300 people
gathering in Cartagena. In Santiago, there were 940 attendees
from 51 countries, reﬂecting the growing momentum and interest
for this ﬁeld in our region. There were 6 short courses, 38
research podiums, 15 workshops, 10 issue panels, and 392
posters. The two plenaries were aligned with the meeting’s
overarching theme, “Increasing Access to Health Care in Latin
America: Making Better Decisions for Greater Equity,” and
focused on how to improve access to health technologies in
Latin America on the basis of methods that are transparent and
fairly representative of all stakeholders’ perspectives [1].
The ﬁrst plenary, “Is HTA [health technology assessment] fair?
Analyzing the HTA process in Latin America & its implications for
access to health care,” was focused on high-level system objec-
tives (such as efﬁciency and equity) and principles (transparency,
or appeal mechanisms). Stimulating presentations by world
experts (Anthony Culyer and Norman Daniels) provided some
insights that challenged mainstream ideas such as the one that
states that efﬁciency and equity cannot be both improved, and
that there is always a trade-off. They also argued how decisions
can be made fairly and represent all stakeholders, while balan-
cing the requirements of a rigorous scientiﬁc method to evaluate
the usefulness of drugs and devices for their populations [2].
The second plenary was “Access to high-cost drugs in Latin
America: Who goes ﬁrst?” This is an important emerging topic in
the region that has been addressed in several developed coun-
tries through the creation of specialized programs that estab-
lished processes that balance equity and efﬁciency principles
according to local jurisdictions. In Latin America, Mexico has
implemented coverage for a number of high-cost drugs for which
prices are negotiated independently by a special commission
created by presidential agreement. However, it represents a
hazard that could allow external pressure to play a role in the
decision-making process, threatening the rational allocation of
resources. In the case of Colombia, multiple health policies have
been implemented to face the challenge of ﬁnancing high-cost
drugs, including the creation of an independent body to centrally
manage funds across all health care subsystems and the devel-
opment of legislation and tools to regulate drug prices. Chile has
recently tackled the issue of access to high-cost drugs through its
public health insurer, the National Health Fund (Fondo Nacionalst: The authors have indicated that they have no
ial support: The authors have no other ﬁnancial rde Salud (FONASA)). This institution implemented a speciﬁc
program in 2007 to fund drugs for certain rare diseases and other
health conditions that require expensive medications, such as
breast cancer and rheumatoid arthritis, which have been pro-
vided to the population on the basis of restricted patient quotas.
In 2015, a law that establishes a new universal fund to cover
high-cost drugs has been enacted. Nonetheless, the organizations
and mechanisms involved in this task are yet to agree on the
procedures and rules that will regulate in practice the provision
of these services in the country, which plan to formally incorpo-
rate HTA tools and principles [3].
Other regional collaborations strengthening outcome research
and HTA are also rather active: some examples are the XIV
Iberoamerican Cochrane Network meeting held during May of
this year in Uruguay [4]; REDETSA’s (regional HTA network) latest
annual meeting held in Chile after the ISPOR regional meeting;
and the ﬁrst upcoming LA HTAi policy forum to be held next
April [5].
In this issue (volume 8, the fourth issue devoted to LA), we can
have an overview of the signiﬁcant progress our ﬁeld is making in
our region. There are studies from the northern to the southern
parts of LA, with several studies from Mexico [6,7] and two from
Chile [8,9]. Researchers from Brazil [10–12] and Colombia [13–17]
continue to produce several articles, but we also ﬁnd articles from
Guatemala [18] and Uruguay [19]. Three of the studies deal with
regional topics and do not deal speciﬁcally with a country-
speciﬁc issue [20–22]. We are publishing not only traditional
cost-effectiveness analysis comparing several technologies, the
site of administration of the treatment (at home vs at hospital
management of pneumonia) [9], or an image archiving metho-
dology, but also a budget impact analysis [11], a systematic
review [22], and a multicenter study using chart reviews [12].
One study examines epidemiological aspects of malaria in our
region, whereas another examines how to estimate dengue-
related costs [21]. The scope of topics being evaluated is
really interesting: some examples are avoidable mortality [13],
inclusion of new drugs into a national beneﬁt package [16],
implementation of patient-reported outcomes [20], consequences
of chemotherapy wastage [23], equity in access to oncological
drugs [19], and unexplained variation in cesarean deliveries [17].
One article focuses on children younger than 5 years [14]. In
summary, we have a very rich 2015 issue, and we deﬁnitely think
our readers will have a lot to enjoy.
And, last but not the least, some other issues: 1) we are in the
queue for National Library of Medicine PubMed/Medline, to be
reviewed in the fall of 2015, for a decision approximately in theconﬂicts of interest with regard to the content of this article.
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journal much more visible and attractive for researchers; 2) this
year we are launching the ﬁrst Value in Health Regional Issues
Excellent Article Award for each region, for articles published in
the previous 2 years. This award will be given to the best article
published in ViHRI from each region biennially; and 3) our journal
outreach is steadily increasing in our rather young existence of
3.5 years. Some metrics are the more than 1600 monthly full-text
downloads, or the nearly 2300 monthly page views in 2015.
Hope that you enjoy the current issue and the buoyant life of
our ﬁeld in LA, aiming to contribute to the use of sound societal
principles for decision making in our region (public and trans-
parent grounds for decisions, relevant reasons, revision mechan-
isms, and enforcement of the previous three) [24].Acknowledgments
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